title: Three-year duration of immunity in cats following vaccination against feline rhinotracheitis virus, feline calicivirus, and feline panleukopenia virus.
abstract: Forty-two seronegative cats received an initial vaccination at 8 weeks of age and a booster vaccination at 12 weeks. All cats were kept in strict isolation for 3 years after the second vaccination and then were challenged with feline calicivirus (FCV) or sequentially challenged with feline rhinotracheitis virus (FRV) followed by feline panleukopenia virus (FPV). For each viral challenge, a separate group of 10 age-matched, nonvaccinated control cats was also challenged. Vaccinated cats showed a statistically significant reduction in virulent FRV-associated clinical signs (P = .015), 100% protection against oral ulcerations associated with FCV infection (P < .001), and 100% protection against disease associated with virulent FPV challenge (P < .005). These results demonstrated that the vaccine provided protection against virulent FRV, FCV, and FPV challenge in cats 8 weeks of age or older for a minimum of 3 years following second vaccination.
authors.affiliation: Intervet Inc., 29160 Intervet Lane, Millsboro, DE 19966, USA.
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Gore
authors.forename: Nallakannu
authors.initials: N
authors.lastname: Lakshmanan
authors.forename: James R
authors.initials: JR
authors.lastname: Williams
authors.forename: Faris F
authors.initials: FF
authors.lastname: Jirjis
authors.forename: S Theodore
authors.initials: ST
authors.lastname: Chester
authors.forename: Karen L
authors.initials: KL
authors.lastname: Duncan
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Coyne
authors.forename: Melissa A
authors.initials: MA
authors.lastname: Lum
authors.forename: Frank J
authors.initials: FJ
authors.lastname: Sterner
mesh_terms: D000818:Animals; D017250:Caliciviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D017927:Calicivirus, Feline / Q000276:immunology*; D002371:Cat Diseases / Q000276:immunology / Q000517:prevention & control*; D002415:Cats; D005254:Feline Panleukopenia / Q000276:immunology / Q000517:prevention & control*; D028301:Feline Panleukopenia Virus / Q000276:immunology; D005260:Female; D006564:Herpesviridae / Q000276:immunology; D007114:Immunization / Q000662:veterinary*; D007117:Immunization, Secondary / Q000662:veterinary; D008297:Male; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D012141:Respiratory Tract Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary / Q000821:virology; D013047:Specific Pathogen-Free Organisms; D013997:Time Factors; D014613:Vaccines, Attenuated; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D014613:Vaccines, Attenuated; D014765:Viral Vaccines